A California federal judge overseeing a $114 million antitrust case against U.S.-based Bayer HealthCare LLC ruled Tuesday that the COVID-19 pandemic isn’t enough reason to allow the generic pet medication company that brought the suit to serve Bayer’s German parent company via email…
Read this piece in its entirety at Law360.